CDB-3963 | 244206-49-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: CDB-3963
• 英文别名: 17α-acetoxy-11β-(4-aminophenyl)-19-norpregna-4,9-diene-3,20-dione；N,N-Didesmethyl ulipristal acetate；[(8S,11R,13S,14S,17R)-17-acetyl-11-(4-aminophenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
• CAS: 244206-49-3
• 化学式: C₂₈H₃₃NO₄
• 分子量: 447.574
• InChiKey: XHVDSLPQGABVRO-WKWWZUSTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,20-bis-ethylenedioxy-5α,17α-dihydroxy-11β-(4-aminophenyl)-19-norpregn-9-ene 在 硫酸 、 potassium hydrogencarbonate 、 对甲苯磺酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 20.5h， 生成 CDB-3963
  参考文献：
  名称：

  Synthesis of N-desmethyl derivatives of 17α-acetoxy-11β- (4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and mifepristone1 Substrates for the synthesis of radioligands

  摘要：

  The syntheses of N-desmethyl derivatives of CDB-2914 and the mono-N-desmethyl derivative of Mifepristone are described. We also describe the use of the mono-desmethyl derivatives as substrates for the synthesis of N-tritomethyl derivatives of CDB-2914 and Mifepristone with high specific activity (ca. 80 Ci/mmol), which serve as radioligands for radioimmunoassay. (C) 1999 Elsevier Science Inc. All rights reserved.

  DOI：

  10.1016/s0039-128x(98)00086-5

文献信息

• PRODUIT DE CO-MICRONISATION COMPRENANT UN MODULATEUR SELECTIF DU RECEPTEUR A LA PROGESTERONE
  申请人：Laboratoire HRA Pharma

  公开号：EP2916823B1

  公开（公告）日：2017-02-15
• PRODUIT DE CO-MICRONISATION COMPRENANT DE L'ULIPRISTAL ACETATE
  申请人：Laboratoire HRA Pharma

  公开号：EP2916871B1

  公开（公告）日：2016-09-14
• DISPERSION SOLIDE D'UN MODULATEUR SELECTIF DU RECEPTEUR A LA PROGESTERONE
  申请人：Laboratoire HRA Pharma

  公开号：EP2928499B1

  公开（公告）日：2018-01-31
• CO-MICRONISATION PRODUCT COMPRISING A SELECTIVE PROGESTERONE-RECEPTOR MODULATOR
  申请人：LABORATOIRE HRA-PHARMA

  公开号：US20150258118A1

  公开（公告）日：2015-09-17

  The subject of the present invention is a co-micronization product comprising: an active ingredient selected from the group consisting of selective progesterone receptor modulators, metabolites thereof and mixtures thereof, and an N-vinyl-2-pyrrolidone-based polymeric excipient. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.
• CO-MICRONISATION PRODUCT COMPRISING ULIPRISTAL ACETATE
  申请人：LABORATOIRE HRA-PHARMA

  公开号：US20150290218A1

  公开（公告）日：2015-10-15

  The subject of the present invention is a co-micronization product comprising an active ingredient selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and a pharmaceutically acceptable solid surfactant. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.